Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Korean Gene Therapies On Horizon, But Slow Regulatory Changes A Drag

Executive Summary

While Korean companies are actively pursuing development of gene therapies, various regulatory restrictions at home are keeping them from speeding up development. But global development continues apace, with interim Phase III results for some expected later this year.

You may also be interested in...



Gene And Cell Therapies In Asia: New Korean Law To Change Landscape Of Cutting Edge Biologics

South Korea will undergo many changes as it gears up for a new law on cutting edge regenerative medicine and biologics, which will be implemented next year. Until then, further discussions will be needed to set details of the rules that can step up the industry’s competitiveness and bring the country more in line with global standards.

Gene And Cell Therapies In Asia: New Korean Law To Change Landscape Of Cutting Edge Biologics

South Korea will undergo many changes as it gears up for a new law on cutting edge regenerative medicine and biologics, which will be implemented next year. Until then, further discussions will be needed to set details of the rules that can step up the industry’s competitiveness and bring the country more in line with global standards.

Interview: ViroMed On Pricing, Manufacturing World’s First Broadly Used Gene Therapy

The head of global business strategy at ViroMed, one of the gene therapy companies nearing the commercial stage in the US, talks exclusively to Scrip about the South Korean biotech’s strategies, including for pricing and manufacturing, which are emerging as key considerations for developers.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

ID1128360

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel